Valuation: Neuland Laboratories Limited

Market Cap 293B 3.08B 2.66B 2.49B 2.28B 4.29B 4.36B 29.19B 11.46B 147B 11.56B 11.31B 486B P/E 2027 *
61.3x
P/E 2028 * 47x
Enterprise Value 296B 3.11B 2.69B 2.51B 2.3B 4.33B 4.4B 29.44B 11.56B 148B 11.67B 11.41B 490B EV / Sales 2027 *
12.1x
EV / Sales 2028 * 10x
Free-Float
62.26%
Yield 2027 *
-
Yield 2028 * 0.2%
1 day-2.21%
1 week+13.91%
Current month+17.16%
1 month+14.46%
3 months+27.30%
6 months+65.66%
Current year+47.06%
1 week 19,205
Extreme 19205
23,450.75
1 month 18,041.55
Extreme 18041.55
23,450.75
Current year 11,500
Extreme 11500
23,450.75
1 year 11,500
Extreme 11500
23,450.75
3 years 3,424.45
Extreme 3424.45
23,450.75
5 years 965.85
Extreme 965.85
23,450.75
10 years 247.3
Extreme 247.3
23,450.75
Manager TitleAgeSince
Chief Executive Officer 47 01/04/2026
Director of Finance/CFO - 23/11/2022
Chief Tech/Sci/R&D Officer - 01/03/2023
Director TitleAgeSince
Director/Board Member 50 01/01/2002
Chairman 82 07/01/1984
Director/Board Member 47 01/03/2007
Change 5-day change 1-year change 3-year change Capi.($)
-2.21%+13.91%+68.09%+457.08% 3.08B
-0.52%+3.21%+89.52%+125.32% 1,057B
+0.88%+1.13%+49.56%+49.79% 625B
+0.89%-1.95%+24.23%+63.19% 435B
+0.71%+3.87%+49.07%+38.29% 363B
+0.64%-0.49%+33.94%+38.94% 296B
+0.39%-5.83%+8.92%+6.39% 249B
+1.51%+6.69%+42.58%+58.47% 222B
+3.92%-0.46%-5.56%-51.70% 209B
+1.80%+2.30%+11.56%+66.16% 165B
Average +0.80%+2.83%+37.19%+85.19% 362.39B
Weighted average by Cap. +0.66%+1.35%+48.74%+64.19%

Financials

2027 *2028 *
Net sales 24.42B 257M 222M 207M 190M 358M 363M 2.43B 954M 12.24B 963M 942M 40.46B 29.28B 308M 266M 249M 228M 429M 436M 2.92B 1.14B 14.68B 1.16B 1.13B 48.52B
Net income 4.8B 50.42M 43.61M 40.73M 37.36M 70.27M 71.39M 478M 188M 2.41B 189M 185M 7.95B 6.26B 65.82M 56.94M 53.17M 48.78M 91.74M 93.2M 624M 245M 3.14B 247M 242M 10.38B
Net Debt 2.56B 26.91M 23.28M 21.74M 19.94M 37.51M 38.1M 255M 100M 1.28B 101M 98.85M 4.24B 979M 10.29M 8.9M 8.31M 7.63M 14.34M 14.57M 97.53M 38.28M 491M 38.64M 37.8M 1.62B
Logo Neuland Laboratories Limited
Neuland Laboratories Ltd. is a global provider of active pharmaceutical ingredients (APIs) contract development and manufacturing organization (CDMO) services. It is focused on manufacture and sale of active pharmaceutical ingredients and allied services. It supports biotechnology and pharmaceutical companies in the design, development and manufacturing of complex APIs. It has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). It develops and manufactures non-exclusive APIs both Prime APIs comprising large volume, mature molecules, and specialty APIs comprising lower volume, complex molecules with less competition. It develops small molecules and peptides for clinical trials and beyond. It provides an end-to-end continuum of customized services from early-stage drug development (Pre-IND) through to commercial manufacturing of complex APIs, including process development, process optimization, analytical testing, and regulatory support.
Employees
2,183
Date Price Change Volume
10/08/26 INR 22,338.85 -2.21% 2,690
07/08/26 INR 22,843.55 +6.25% 12,785
06/08/26 INR 21,499.95 +7.69% 80,622
05/08/26 INR 19,964.70 +3.51% 2,844
04/08/26 INR 19,288.35 -1.64% 843
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
22,843.55INR
Average target price
24,334.75INR
Spread / Average Target
+6.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NEULANDLAB Stock